Gufic Biosciences (509079) Q2 24/25 earnings summary

Executive summary

• Indore facility commissioned and operational, marking a transformative milestone with phased production ramp-up and regulatory alignment for domestic and international markets.

• Strategic business units expanded, including Critical Care, Ferticare, Aesthaderm, Neuro Care, Sparsh, Spark, Stellar, and Healthcare, each targeting specific therapeutic areas and market needs.

• International business growth driven by new market approvals, including a UK NHS tender and expansion in Thailand, Sri Lanka, Cambodia, and Lithuania.

• Focus on high-barrier products, clinician engagement, and innovative launches across divisions to drive growth and market positioning.

• Revenue and net profit for H1 FY25 remained stable year-over-year, reflecting consistent performance.

Financial highlights

• H1 FY25 revenue at ₹407 crore, nearly flat versus ₹409.9 crore in H1 FY24; Q2 FY25 revenue at ₹204.2 crore, down from ₹214.9 crore in Q2 FY24.

• H1 FY25 EBITDA at ₹79.8 crore (margin 18.62%), up from ₹76.1 crore (18.57%) in H1 FY24.

• H1 FY25 PAT at ₹42.6 crore (margin 10.47%), slightly lower than ₹43.8 crore (10.69%) in H1 FY24.

• Cash generated from operations for H1 FY25 was ₹8,940.77 lakhs, a significant increase from ₹1,229.55 lakhs year-over-year.

• FY24 revenue was ₹808.8 crore, EBITDA ₹148.0 crore (18.3% margin), and PAT ₹86.1 crore (10.6% margin).

Outlook and guidance

• Indore facility expected to contribute minimally to revenue in FY25, with significant impact anticipated over the next two to three years.

• EU and US regulatory approvals targeted, with EU audit expected by late 2024 and USFDA action anticipated in 2026.

• CMO/CDMO business to commence in late 2024, supporting long-term international growth.

• Plans to increase market share in botulinum toxin, expand contract manufacturing, and commercialize immuno-oncology therapy.

• Continued investment in international registrations and manufacturing scale-up to support global expansion.